The Wegovy pill’s ‘surprise miss’ is one reason Novo Nordisk’s stock is down

Novo Nordisk released updated financial guidance for 2026. The company announced results for a tablet formulation of its weight-loss medication, which did not meet specified efficacy targets in clinical trials. Novo Nordisk's stock price declined following the announcement.

Next story